Clinical Trial Update: DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating DFP-10917 in combination with venetoclax for relapsed or refractory acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DFP-10917
• Venetoclax (venetoclax)

Snippet

Sponsor: Delta-Fly Pharma, Inc. | Conditions: Leukemia, Myeloid, Acute | Phase 1, Phase 2 | Status: RECRUITING